Sotagliflozin Lowers A1c, Weight Even in Kidney Impairment

ORLANDO, Florida — Sotagliflozin (Inpefa) reduces A1c and body weight in people with type 2 diabetes, although the degree of improvement was attenuated in those with moderate-to-severe chronic kidney disease (CKD).  “These findings highlight the importance of considering the effect of kidney function to help inform and tailor treatment decision-making for patients with diabetes and …